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Adherence: Refers to compliance or obedience to a medication regimen exactly as 
prescribed by a health care provider (PAGAA, 2008). 
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First-line therapy: One of four recommended combinations of non-nucleoside reverse 
transcriptase inhibitor based drug regimens used at the initiation of treatment of a drug 
naive HIV positive patient (MOHSS, 2007). 
Self-reported dose adherence: This is a measurement of therapy dose compliance based 
on a patient recalling medicine taken in the last 3 days (Steel et al, 2007). 
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Tuberculosis: This is the medically reported presence of mycobacterium tuberculosis 
infection in the patient. 
 (CD4) at the initiation of ARV therapy. 
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ABSTRACT 
Introduction: Antiretroviral regimens have side effects that can threaten adherence by 
patients resulting in evolution of viral resistance due to suboptimal drug levels. Studies 
have shown that drug adherence of at least 80% can result in viral load suppression.  
There is no literature on the association between the level of adherence to antiretroviral 
therapy and the degree of virological suppression in Namibia. The aim of the present 
study was to determine the therapeutic and virological outcomes in HIV/AIDS patients at 
6 and 12 months after initiation of highly-active antiretroviral therapy (HAART) in an 
urban population in Namibia. 
Materials and Methods: An observational cross-sectional retrospective review of 
patient care booklets for patients initiated on HAART at Katutura Health Centre, 
Namibia during the period January 1st - December 31st
Results: Of 687 patients initiated on first-line HAART during the year under review, 508 
(74%) patients met the eligibility criteria. At 6 months, 88% and 92% of patients had 
viral load <400 copies/ml and <1000 copies/ml, respectively. Whereas, at 12 months, 
70% and 88% of patients had viral load <400 copies/ml and <1000 copies/ml, 
respectively. At 6 months the self-reported HAART dose adherence of ≥95%  adherence 
 2007. Viral load results were 
placed into categories of <40 copies/ml, 40-399 copies/ml, 400- 999 copies/ml and >1000 
copies/ml at the 6 and 12 months time points. Self-reported dose adherence at 6 and 12 
months was classified as good (≥ %95), fair (85 -94%) and poor (<85%). The prevalence 
of ≥95% adherence at 6 and 12 months of initiating therapy was calculated. Patients with 
viral load ≥400 copies/ml were then compared with those with a viral load <400 
copies/ml at 6 and 12 months. 
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was 84% and 88% at 12 months. Poor virological outcome (viral load ≥400 copies/ml ) 
was significantly associated with poor self-reported prophylaxis adherence and self-
reported ARV dose adherence at 6 and 12 months.  
Conclusion: The distribution of viral load results showed a low uptake (35%) of 
virological monitoring at 6 month time point and even lower (12%) at 12 months. A 
conservative viral load threshold for virological response is required in the Namibian 
setting. The current adherence level of >80% encourage increased ARV therapy rollout. 
Poor virological outcome was associated with self-reported adherence.  
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1. INTRODUCTION 
1.1 Background 
Namibia is one of the seven countries most affected by HIV/AIDS in sub-Saharan Africa 
(MOHSS, 2004). According to the 2008 HIV Sentinel Survey, Namibia has an HIV prevalence of 
17.8% (MOHSS, 2008). The Estimation and Projections Package (EPP) model that calculates 
national HIV prevalence based on ANC HIV prevalence and other information had results for 
Namibia that suggested adult (15-49 years) prevalence in 2007/2008 of 15.4% (MOHSSb, 2008). 
The EPP estimated 204 000 people to be living with HIV in 2007/2008 and this number is 
projected to grow as the total population size of the 15-49 year age group grows. According to the 
Namibian Spectrum model, linked to EPP model, in 2007/08 there were approximately 14100 new 
infections with 50600 individuals (adults and children) receiving ARV therapy and an estimated 
63600 adults were in need of ARV therapy by end of March 2008 (MOHSSb, 2008). While the 
deaths due to AIDS were approximately 5400 persons (plausibility bounds: 3700-7300) (MOHSSb, 
2008). 
 
In order to curb the high mortality and adverse socioeconomic effects of the HIV/AIDS pandemic, 
in 2003 the MOHSS started providing ARV therapy to patients meeting defined clinical criteria 
(MOHSS, 2004).   However, expanded ARV therapy came with the challenge of maintaining 
treatment adherence among a growing number of ARV patients and the need to improve patient 
management and care (Steel et al, 2007; Dyul et al, 2002; San Lio et al, 2008; Pierson et al, 2000). 
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Another challenge has been to minimize the emergence of drug-resistant HIV strains in HIV-
patients receiving treatment.  
 
Antiretroviral therapy clinics have been opened around the country through collaboration of the 
MOHSS and donor organizations and one such clinic is the Katutura Health Centre. The ARV 
clinics operate based on set guidelines and protocols such as the HAART protocol for patient 
management and the MOHSS circular stating the use of laboratory tests for patient monitoring 
(MOHSSa, 2007; MOHSS, 2005). According to these guidelines, there are four recommended 
combinations for first-line therapy and they are all NNRTI based drugs. The laboratory test panel 
includes the HIV viral load at six months and CD4 counts every three months.  The optimal 
response to treatment has been given as a median CD4 cell rise of 100 to 200 cells within the first 
year (MOHSS, 2007). 
 
The infrastructure for viral load testing is in place at the local parastatal referral laboratory. The 
challenge however is to ensure the use of the viral load and the CD4 results to make patient 
management decisions. The guidelines do not present any expected viral load values, thus an 
undetectable status of viremia has by default become the expectation. This study sought to 
determine the viral load levels that can be expected under the current adherence practice, 
monitoring techniques and other underlying factors. It is hoped this will aid clinicians in decision 
making in HAART patient management. 
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1.2 Research setting 
Namibia is a vast country with a population of approximately 2 million most of who are relatively 
young with 43% under 15 years and 4% are over 65 years (MOHSSc, 2008). Namibia has very 
diverse ethnicity, there are 11 indigenous languages that are spoken but English is the official 
language. Although the country is classified as a middle income country, it has one of the largest 
differentials between rich and poor in the world (MOHSSc, 2008).  
 
The health delivery system is under 13 regional directorates with 34 health districts. This structure 
has a national referral hospital (Windhoek Central Hospital), 3 intermediate/ referral hospitals ( 
Oshakati, Rundu and Katutura Hospitals), 30 public district hospitals, 44 health centres, 265 clinics 
and 1150 outreach sites (MOHSSc, 2008). Katutura Health Centre is one of the 44 health centres 
around the country. The Centre is situated within the Khomas region in the proximity of the capital 
city, Windhoek and is located in the heart of Katutura, the largest high density settlement in 
Windhoek. The ARV clinic is a stand alone facility within the Katutura Health Centre grounds and 
is open from Monday to Friday with Tuesdays reserved for initiating new patients on ARV therapy. 
The current rate of initiating therapy is approximately 30 patients per week as of 15 July 2008, and 
prior to this date it was 15 patients per week. Due to increased uptake of the HIV care services at 
the Centre initiation of patients to HAART was doubled on 15 July 2008 to increase access to ARV 
therapy. 
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Based on ARV therapy guidelines, an HIV-positive person is evaluated for eligibility to begin 
ARVs at an ARV clinic such as this study’s research site, Katutura Health Centre. The assessment 
includes medical history, HIV disease directed physical examination to determine WHO clinical 
staging, CD4 count and a review of social eligibility (MOHSS, 2007). At the first visit, all patients 
are registered into the AMIS. A patient care booklet (Appendix 1) is utilised to capture baseline 
and monitoring data for each individual patient enrolled for HIV care in the clinician cubicles. The 
data is then entered by a data clerk to update the patient AMIS record. The patient keeps a card 
with a unique identifier that is the file number for the patient care booklet and AMIS record. A 
patient on HIV care is then initiated on ARV therapy when they have: 
• WHO clinical stage 3 or 4 HIV disease irrespective of CD4 count, or 
• CD4 cell counts ≤ 200 cells/mm 3 ( ≤ 250 cells/ mm3 
• Met social eligibility criteria, namely: 
 for pregnant women), irrespective of 
WHO clinical stage and 
 Have a fixed address for the past 3 months 
 Have a treatment supporter ( but should not be the sole reason to deny treatment) 
 Have ready access to a designated treatment centre for follow-up 
 Not drink alcohol 
 Have no untreated underlying psychiatric disorders  
 Be committed to lifelong treatment with HAART, strict adherence to treatment, practising 
safe sex and allowing home visits (MOHSS, 2007). 
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Initiating a patient on ARV therapy requires > 2 visits at least 2 to 4 weeks apart to ensure 
readiness. Antiretroviral dose adherence is then measured through use of self-reporting of > 95% of 
medication taken within the previous three days. The laboratory monitoring of therapy includes the 
measurement of HIV viral load and this is performed by the reference laboratory, Namibia Institute 
of Pathology.  
 
1.3. Problem statement 
There is limited data available in Namibia on adherence of adult HIV-infected patients to HAART 
regimens as assessed by self-reporting at 6 months and 12 months after initiating ARV therapy. 
The proportion of these patients that have virological failure and their corresponding demographic, 
clinical and social characteristics is unknown. This information is vital for the assessment of drug 
efficacy and the virologic effect of therapy as well as determining the continuation or change of 
therapy. 
 
1.4. Purpose 
This study seeks to provide data on level of self-reported dose adherence, distribution of viral load 
levels and the characteristics of patients with viral load ≥400copies/ml after initiating ARV therapy 
at Katutura Health Centre. This information can assist clinicians in the management and care of 
patients when assessing the virological effect of therapy and provide insight for recommendations 
in future guidelines in terms of viral load assay result usage in therapy continuation or change.   
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1.5. Aim 
The aim of the study was to determine the therapeutic and virological outcomes in adults living 
with HIV/AIDS at 6 and 12 months after initiation of HAART in Katutura Health Centre in 
Namibia in 2007. 
 
1.6. Specific Objectives 
1. To describe the proportion of adult patients who had viral load measures recorded in their 
patient record at 6 and 12 months after initiating first-line HAART in 2007. 
2. To describe the recorded viral load levels of the adult patients at 6 months and 12 months after 
initiation of first-line HAART in 2007. 
3. To assess the adult patient self-reported dose adherence levels to first-line HAART at 6 and 12 
months after initiation of first-line HAART in 2007. 
4. To characterize and compare adult patients who achieved < 400 copies/ml and ≥ 400 copies/ml 
virological suppression at 6 and 12 months after initiation of first-line HAART in 2007. 
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2. LITERATURE REVIEW 
The literature review starts with a review of the use of medical records and the general background 
to ARV therapy. This is followed by a review of literature on treatment adherence, viral loads and 
their relationship in ARV therapy and patient management. The section further highlights the 
various methods used in the identified studies. Firstly however, the debate on the use of medical 
records shall be discussed.  
 
2.1  Use of medical records in research. 
The use of medical records for research has been debated in the international community, debating 
the need for individual patient consent when conducting studies (Wald, Law, Meade, Miller, 
Alberman and Dickinson, 1994; Robling, Hood, Pill, Fay and Evans, 2003; Al-Shahi and Warlow, 
2000). The debate arose when the European Commission proposed guidelines for use of medical 
records in research (Wald et a, 1994). Wald et al, 1994 highlighted the value of systematic record 
reviews and record linkage studies in expanding knowledge and improving medical practice. Al-
Shahi and Warlow, 2000 suggested that need for consent in observational studies would introduce 
systematic bias, caused by refusal of patients to use their data. Wald et al, 1994 recommended the 
use of the guidelines of the Royal College of Physicians working group that advocates for medical 
record use as long as a “confidential manner without causing harm” is practiced.  
 
The use of medical records is an inexpensive and efficient way of gaining a comprehensive view of 
the health system’s response to a particular medical problem (Merion& Cash, 2006). However, in 
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the past few years the debate was on issues of informed consent and confidentiality. Merion and 
Cash, (2006) argue that obtaining informed consent may cause breach of privacy, undue 
psychological or social harm to a former patient, introduce bias and financial strain for studies. 
They also however conclude that confidentiality issues are likely to gain importance.  
 
International guidelines were formulated that require ethical clearance for all studies. In Africa the 
reality for the need of ethical review boards came with the increased collaborative studies based on 
the Millenium development goals (Kigira, Wambebe and Baba-Moussa, 2005). Kigira, Wambebe 
and Baba-Moussa, 2005 performed a descriptive study to determine which WHO African region 
member countries had ethical review boards. They found that of the 28/46 countries that responded 
only 64% (18/28) confirmed the existence of national research committee. Although Namibia is not 
sited in this article as a respondent, there is an ethical review board present in the country. This 
study sort ethical approval to conduct the study based on national requirements and international 
standards. The approval letters can be found in Appendix 4 and 5. 
 
2.2 Background to antiretroviral therapy 
The HIV pandemic has now evolved to an era of ARV therapy.  As ARV therapy is becoming 
more accessible to the general population and with the rapid evolution of information, interest is 
shifting to the use, monitoring and challenges of treatment regimens and maintaining treatment 
adherence (Steel, Nwokkie and Joshi, 2007; Dyul et al, 2002; San Lio et al, 2008; Pierson et al, 
2000). Antiretroviral regimens are complex with serious side effects that pose difficulty with 
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adherence resulting in evolution of viral resistance due to non-adherence and suboptimal drug 
levels (Dyul et al, 2002). Generally, adherence of greater than 95% is required for good results to 
NNRTI based regimen (San Lio et al, 2008). However, Bangsberg et al (2006) and Martin et al 
(2008) have shown that adherence levels of 80-90% to combination regimens will still result in 
viral load suppression. There is no literature on the association between the level of adherence to 
ARV therapy and the degree of virological suppression in Namibia.  
 
The assessment of ARV treatment failure involves the initial consideration and assessment of 
patient adherence, tolerability and pharmacokinetic issues (PAGAA, 2008). This is then followed 
by assessment of clinical progression, immunological and virological failure. Clinical progression 
is defined as the occurrence and recurrence of HIV-events after at least 3 months on treatment 
(PAGAA, 2008). Immunological failure is when an adequate CD4 response is not achieved or 
maintained (PAGAA, 2008). Virological failure is the inability to suppress viral load below 
detectable levels and may manifest as incomplete virologic response or virologic rebound 
(PAGAA, 2008). The solution to clinical progression, immunological and virological failure is 
treatment change. Unfortunately ARV regimen change is not a decision to be taken lightly as the 
drugs can lead to serious side-effects. There is also the cost of switching regimen and a problem of 
limited further options that may be exacerbated by the possibility of adverse events and the chance 
of drug resistance.  
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The change of ARV regimen requires a thorough drug treatment history with review of results of 
drug resistance testing (Dyul et al 2002). The threat of drug resistance has resulted in a set of early 
warning indicators being published (WHO, 2006). Shiningavamwe (2008) however showed no 
detectable (< 5% threshold) resistance levels among treatment-naïve pregnant women in Namibia. 
The study highlighted the need to revert to initial assessment considerations of adherence, 
tolerability and pharmacokinetic issues as causes of ARV treatment failure. Descamps et al (2000) 
carried out a case-control study over a period of 10 months in 3 urban hospitals in France and 
showed that the early and late virologic failures during the maintenance phase are related more to 
problems of adherence and ARV treatment potency than to resistant mutant strains. Furthermore 
the superior nature of NNRTI based regimens over single protease inhibitor regimen has been 
closely associated with regimen potency over higher levels of adherence (Weiser, Guzman, Riley, 
Clark and Bangsberg, 2004).  
 
The current study therefore sought to describe self-reported dose adherence and viral load patterns 
as background information that can be utilised in the initial assessment of ARV treatment failure. If 
the patterns are known, then the prevalence of adherence as a cause of ARV treatment failure is 
considered appropriately. Furthermore, the viral load patterns encompass the tolerability and 
pharmacokinetic issues, as the patterns reflect response rates that can be expected in the Namibian 
setting of ARV therapy and virological monitoring.  
 
2.3 Adherence to ARVs 
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The measurement of ARV adherence is essential for targeting and rigorously evaluating 
interventions to improve adherence and prevent viral resistance (Berg &Arnsten, 2006). Harries, 
Nyangulu, Hargreaves, Kaluwa and Salaniponi (2001) and Stevens, Kaye and Corrah (2004) 
reported concerns for the rapid access to ARV therapy in Africa. They concurred that it may lead to 
transmission of resistant strains as they believed a high proportion of patients in Africa would 
poorly adhere to treatment regimens. However, this theory was contested by Mills et al (2006) 
when their meta-analysis on adherence patterns revealed that patients in Africa (resource-poor) had 
adherence levels of 77.1% (95% CI: 67.3%-85.6%) which is equal and possibly better than North 
America (resource-rich) with 54.7% (95% CI: 48.0-61.3%). The varied estimates of adherence 
reported in the meta-analysis reveal the lack of standardization for adherence measures, which shall 
now be reviewed in the following section.  
 
2.3.1 Methods for measuring adherence to therapy 
Adherence measures include the visual analogue scale or pill identification test where a patient is 
asked to identify their medication, self-reporting of medicine taken in the past 3 days, pill counts of 
medication left in the vial at a visit (and unannounced version) and the medication possession ratio 
(MPR) - a metric that correlates to virologic outcomes (Steel et al, 2007; Chi et al, 2009).  The 
limited understanding of how to optimize existing adherence measures has delayed progress in 
adherence research (Berg &Arnsten, 2006).  
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Self-reporting is the most widely used adherence measure and the most promising for use in 
clinical care and resource limited settings (Berg &Arnsten, 2006). This method is currently in use 
in Namibia as it is inexpensive and simple to use in the clinical setting, however it grossly over 
estimates adherence (Liu et al, 2006). Liu et al (2006) recommended the evaluation of calibrated 
patients self-reporting with duration of ARV regime and attitudinal measures (patient attitude and 
psychological factors) as they impact on the level of adherence. Unfortunately, self-reported 
adherence is not a precise predictor of treatment success to substitute for viral monitoring (Garcia 
et al, 2006). Hence Namibia introduced the viral load at 6 months after initiation of therapy to 
predict treatment response. 
 
Objective measures such as pill counts are not as widely used with one reason being poor 
understanding of the source and magnitude of error biasing the methods (Berg &Arnsten, 2006). 
The use of unannounced monthly pill counts with pillbox organizers has appeared to improve 
adherence and virologic suppression (Petersen et al, 2007). The visual analogue is considered to be 
simple and potentially useful in routine patient care (Giordano et al, 2004). However it has been 
found that the visual analogue scale and unannounced pill counts are not different from the 3 day 
recall (Giordano et al, 2004). The MPR is a pharmacy-based measure of adherence. The MPR is 
calculated by dividing the number of days of medication supplied within a refill interval with 
number of days in refill interval (Peterson et al, 2007). If the MPR is calculated over multiple 
refills it is also referred to as the continuous measure of adherence. The MPR has been correlated 
to clinical outcomes in both developed and developing country settings (Chi et al, 2009).  
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The current study utilised the self-reporting of medication taking behaviour as a measure of 
adherence as it is not only in use in Namibia but also widely adopted in other resource limited 
settings. Since the self-reporting of adherence does not replace virological monitoring in Namibia, 
the association between the two was also analysed. 
 
2.3.2 Studies on adherence to ARV therapy 
Since adherence to ARV therapy is a topical issue, studies are being carried out all over the world 
in both developed and developing settings. The studies on adherence to ARV therapy are designed 
in various formats. Some are prospective observational studies (San Lio et al, 2008; Amberbir, 
Woldemchael, Getachew, Girma and Deribe, 2008; Martin et al, 2008; Nilsson, Schonnesson, 
Diamond, Ross, Williams and Bratt, 2006 and Laniece et al, 2003). Other studies have used a 
cross-sectional approach and retrospective review of patient clinical history (Weiser et al, 2003; 
Uzochukwu et al, 2007 and Chi et al, 2008). The studies reviewed were carried out over various 
time frames. Sample population and size was based on predetermined eligibility criteria for the 
setting. Cross-sectional studies and retrospective record reviews are the preferred study designs in 
research settings where resource constraints and time are important considerations. When taking 
into account the various methods of measuring adherence mentioned in the above section, sample 
size, study setting and study design, comparison of study findings is a challenge. However, the 
following sections shall describe studies on ARV adherence and their findings, highlighting the 
various differences in methodology.  
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A 12 month prospective observational study in Mozambique of patients receiving first-line 
HAART utilized the pill count as an adherence measure (San Lio et al, 2008). Out of a total of 531 
participants, 137 (25.8%) patients left the program or discontinued first-line therapy by the end of 
the 12 month period. Of the 394 patients remaining 284, 72.1% of their patients had >95% 
treatment adherence. Of these adherent patients 96.5% had a final viral load of < 1000 copies/ml. 
Amberbir et al (2008) in their prospective study in South- West Ethiopia using a self-reported dose 
adherence as a measure found adherence of 94.3% in the first month and this decreased by 2% by 
the third month. Another prospective study carried out in Sweden used self administered 
questionnaires and medical records in a two year period (Nilsson et al, 2006). The study cohorts 
were patients that completed at least six of the seven follow-up questionnaires. Their study 
revealed that 61% of the patients maintained full-dose adherence (Nilsson et al, 2006). These two 
studies though two years apart, suggest reduction in adherence overtime in both developed and 
developing countries.  
 
Chi et al (2009) utilized the MPR method as a retrospective adherence measure for a large cohort 
of treatment naïve adults initiating and continuing ARV therapy for ≥ 12 months in Zambia. They 
found 62.9% of patients had optimal adherence (≥ 95%), 28.3% had sub -optimal (80-94%) and 
8.8% had poor adherence. A cross-sectional study using pre-tested interviewer- administered 
questionnaires in Nigeria from randomly selected 174 patients on treatment over the past 12 
months revealed that approximately 25% of patients had adhered to the treatment regimen 
(Uzochukwu, Onwujekwe, Ndu, Okoli and Onoka, 2007). With sample size and study design 
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differences, the variation in adherence is hard to interpret. Other factors showing great variation in 
the studies reviewed are the determinants of adherence. This shall be the topic of the next section. 
  
2.3.3 Determinants of adherence 
The reported determinants of adherence to ARV therapy include social support, psychological and 
cognitive factors, use of memory aids, self-efficacy, age, number of doses a day and other 
sociodemographic variables such as the number of years of schooling, unemployment, alcohol use, 
self-reported adverse events, number of pills, financial constraints, stigma, travel/migration, switch 
of regime and increase lag time between HIV test result and first ARV prescription (Pinheiro, de-
Carvalho-Leite, Drachler and Silveira, 2002; Amberbir et al, 2008; Gordillo, del Amo, Soriano and 
Gonzalez-Lahoz, 1999; Duong et al, 2001; Bonolo et al, 2005; Nilsson et al, 2006; Weiser et al, 
2003; Laniece et al, 2003). These determinants and the direction of predictions in relation to ARV 
adherence shall now be reviewed in more detail. 
 
Pinheiro et al (2002) carried out a cross-sectional study in a Southern Brazil referral service and 
concluded that the most important determinant of adherence is increased self-efficacy. Self-
efficacy is a persons’ conviction on successful execution of certain behaviour to produce a desired 
outcome, in this case taking prescribed medication. The other determinants reported in this study 
for increased adherence were decreased frequency of medicine taking and greater than 8 years of 
schooling. Bonolo et al (2005) carried out a prospective study in referral centres in Brazil over a 2 
year period. The study confirmed an earlier finding by Pinherio et al (2002) when number of pills 
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per day increased risk of non-adherence. The study also found unemployment, alcohol use, >2 
adverse reactions, switch of regimen and a longer time between HIV test result and first ARV 
prescription to be associated with increased risk of non-adherence. These two studies which were 
both conducted in Brazil show how determinants of adherence can vary even within country. 
Hence, a recommendation to incorporate feasible and reliable adherence indicators in routine 
monitoring of adherence in clinical practice (Bonolo et al, 2005). The patient care booklet used as a 
data source in this current study incorporates a section on the demographic and treatment profile of 
the patient.  
 
A cross-sectional study in Spain showed decreased ARV adherence to be associated with 
depression, lack of self-perceived social support, intravenous drug users and younger individuals 
(Gordillo et al, 1999). These determinants in essence can be classified as psychological and 
behavioral which is in agreement with the findings of Duong et al (2001). Duong et al (2001) 
evaluated the Patient Medication Adherence Questionnaire in France and found that motivation to 
treatment, confidence in personal skills and an optimistic attitude to life as determinants of 
adherence. Thus they concluded that psychological and behavioral factors are central to adherence. 
They however excluded any association between lower medication adherence and 
sociodemographic background, social support, alcohol and illicit drug use and depression.   
 
In the African setting, social support, use of memory aids and lack of depression were found to be 
positive predictors of adherence in Southwest Ethiopia (Amberbir et al, 2008). Interestingly, the 
 
 
 
 
  
17 
study demonstrated that the determinants also varied over time. Initially, social support and lack of 
depression were positive predictors, but at a 3 month follow-up, it was social support and use of 
memory aids that predicted adherence. In Botswana the principal barriers to adherence were 
financial constraints, stigma, travel/migration and side-effects, listed in decreasing order of 
negative determinants (Weiser et al, 2003). A cross-sectional study done in Senegal echoed the 
finding of cost as a barrier but also included the type of drug regimen (Laniece et al, 2003). In 
Namibia, therapy cost is subsidized due to funding organisations collaborating with the Ministry of 
Health. However, transport and other financial constraints are not subsidized.  
 
The above review highlights the vast variation in the direction of prediction of ARV adherence 
determinants in different settings. It is therefore vital to assess determinants of adherence in a local 
setting. The within country variation in Brazil underscores this. Since adherence is a dynamic 
process that cannot be predicted with the use of a few characteristics, a recommendation to 
integrate adherence support into regular clinical follow-up was put forward (Bonolo et al, 2005; 
Amberbir et al, 2008). Although adherence support in the form of counseling and patient education 
has been integrated in the Namibian setting, the assessment of determinants of adherence is notably 
limited. The current study sought to describe the characteristics of patients with possible 
virological failure (viral load ≥400copies/ml) as an outcome of non-adherence to ARV therapy.  
 
2.3.4 Adherence and clinical outcome 
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The goal of adherence to ARV therapy is to improve clinical outcome by achieving undetectable 
levels of HIV viral load and increasing immunological response (WHO, 2000). The overall 
outcome is to prevent disease progression from HIV infection to AIDS, hence reduce HIV 
morbidity and mortality within the HIV positive population. This prevention phenomenon has far 
reaching socioeconomic consequences in a population. The reported clinical outcomes from studies 
shall now be reviewed below. 
 
San Lio et al (2008) assessed the risk associated with ≤ 95% treatment adherence having a viral 
load > 1000 copies/ml compared to those with an adherence of > 95 utilizing the Mantel-Haenszel 
procedure. The estimated odds ratio was found to be 5.11 (95% CI: 2.26- 11.54). The study also 
applied a Cox proportional hazard model to calculate the hazard ratios of having a viral load ≥ 
1000 copies/ml in relation to adherence, CD4 cell count and age. The model found significant 
association with age <30 years, initial CD4 count <338 cell/mm3
 
 and having a viral load >1000 
copies/ml. They explained that age < 30 years may be a behavioral marker that results in poor 
virological outcome. In terms of an initial CD4 count, San Lio et al (2008) suggested that it is a 
marker of disease progression and health status at initiation of ARV therapy. Thus a poorer level of 
health and more advanced disease progression at initiation of ARV therapy results in poorer 
clinical picture even after 12 months.  
Chi et al (2009) in a cohort of patients in Zambia confirmed San Lio et al (2008) Mozambique 
findings when they reported that individuals >35 years of age or reported social support (an 
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adherence buddy) were less likely to exhibit poor clinical outcome. When they compared post-12-
months mortality risk they found it to be similar for optimal and suboptimal adherence but higher 
in those with poor adherence. Unfortunately, their study findings on mortality risk may have been 
confounded by selection bias since their population was composed of patients that had survived the 
periods of highest mortality risk, first 90 days on ART or at least 12 months (Chi et al, 2009). 
 
Ledergerber et al (1999) had earlier reported significant association with increases in CD4 count 
(immunological response) at 6 months with a favourable clinical stage at baseline of ARV therapy 
initiation. A South African work-based cohort also reported independent predictors of suboptimal 
virological outcome as <1 log decrease in viral load at six weeks, WHO stage 3 and 4, baseline 
viral load at baseline > 100000 copies/ml and site of ART delivery (Fielding et al, 2008). They 
suggested that poor virological outcome at 6 weeks (<1 log decrease in viral load) was more likely 
due to poor adherence than to transmitted resistance since their study population had very little 
prior ARV therapy. The poor outcome associated with site of delivery was interesting as all sites 
use the same guidelines, counseling protocols and drug regimens. Through their experience, they 
suggested long waiting times for clients, staff not being specially trained in HIV care, poor follow 
up of patients not attending the clinic or lack of communication between the pharmacy and clinic 
staff as possible causes (Fielding et al, 2008). Most resource limited settings do not assess baseline 
viral load, including Namibia.  
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The current study describes patient characteristics with virological outcome of ≥400 copies/ml at 6 
and 12 months to identify factors that may be associated with poor outcome. It is hoped the 
findings will assist in patient management. 
 
2.4 HIV viral load 
The viral load is a quantification of circulating HIV ribonucleic acid (RNA) copies per milliliter 
(copies/ml) and can also be expressed as a log value. A change of 0.5 log10
 
 is considered 
statistically significant (WHO, 2008). The viral load is a predictor of risk of HIV transmission, 
with it being rare at <1500 copies/ml, while a baseline viral load >100 000 copies/ml is related to 
increased mortality rates (Fielding et al, 2008; Quinn et al, 2000; Wood et al, 2006). HIV RNA is a 
surrogate marker for treatment response and is thus used for efficacy monitoring of ARV therapy 
(WHO, 2008; WHO, 2000). The goal of HAART is to reduce the viral load to undetectable levels 
(WHO, 2000). There are three Food and Drug Agency approved viral load assays with the 
following detection limits, the Amplicor (<40 copies/ml), Versant (<75 copies/ml) and the 
Nuclisens (<80 copies/ml). The Amplicor assay is currently in use in Namibia. The goal of 
undetectable levels should be achieved in 16- 24 weeks (WHO, 2008). Thus some studies have 
considered putting patients with undetectable viral load on maintenance regimes to reduce therapy 
costs and pill burden (Flandre et al, 2002 and Pia loux et al, 1998).  
An audit of a clinical population in England revealed 92% of patients on therapy for more than 16 
weeks had a viral load of <50 copies/ml (Madge et al, 2008). Thus they concluded that the 
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proportion of patients with viremia was low in their current clinical practice. In a study done in 
Mozambique, the findings were that 96.5% of patients had <1000 copies/ml at 12 months when 
adherence was > 95% (San Lio et al, 2008). This finding echoes the one in England in terms of 
viremic prevalence if >1000 copies/ml is used as the threshold. In Namibia there has been no study 
to find the association between adherence and virological outcome. This current study therefore 
seeks to provide insight.  
 
Fielding et al (2008) reported the viral load at 6 weeks as the strongest predictor of suboptimal 
outcome at 12 months. Inexplicable increases in viral load have been observed and are referred to 
as “blips”. The “blips” were found not to warrant change in treatment (Havlir et al, 2001; Lee, 
Keiffer, Siliciano and Nettles, 2006). These transient events only result in treatment failure in < 
10% of cases kept on the same regimen (Garcia-Gasco et al, 2008). Thus, a conservative threshold 
of > 400 copies/ml is used to classify patients at risk of failing therapy to accommodate the “blip” 
phenomenon (Madge et al, 2008; Phillips et al, 2008). This conservative threshold of >400 
copies/ml was also adopted in the current study. There are recommendations as to the frequency of 
viral load monitoring, as summarized in Appendix 2 (WHO, 2008). There are also guidelines for 
resource unlimited and resource limited setting for patients that have initiated HAART therapy 
(WHO, 2000, WHO, 2008). In the case of Namibia, a resource limited setting, a clinical review one 
month after initiating treatment, with assessments every 3-6 months is recommended. However in 
Namibia, due to the high cost of viral load testing, the viral load is only done at 6 months after 
initiating therapy and then thereafter as clinically indicated (MOHSS, 2005). Despite the 
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availability of recorded data of viral load, no study had been carried out in Namibia to determine 
viral load patterns of ARV therapy patients. Hence it is one of the objectives of this study. 
 
2.5 Relationship between adherence and HIV viral load 
The adherence to HAART is essential and closely associated with time on treatment and decrease 
in HIV viral load (Nieuwkerk & Oort, 2005; Bangsberg et al, 2003). The visual analogue scale and 
unannounced pill counts are not different from the 3 day recall although they are inversely 
correlated to HIV viral load (Giordano et al, 2004). A meta-analysis of studies on the relationship 
between self-reported adherence and viral load has shown that self-reported adherence measures 
can distinguish between clinically significant patterns of medication taking behavior (Nieuwkerk & 
Oort, 2005). Nieuwkerk & Oort (2005) indicate that confidentiality of responses, use of actual viral 
load measurements, an adherence level of lower than 95% and higher percentages of patients with 
intravenous drug use are significantly associated with the relation between adherence and virologic 
response. Increasing rates of viral suppression at high levels of adherence are balanced by 
increasing rates of drug resistance among viremic patients (Bangsberg et al, 2003). Bangsberg et al 
(2003) highlighted that exceptionally high levels of adherence will not prevent population levels of 
drug resistance. Discordant adherence-response relationship has been reported in Botswana, were 
very high rates of adherence were associated with virological failure (Bisson, Rowh, Weinstein, 
Gaolathe, Frank and Gross, 2008). Once again, there is no literature on the adherence-response 
relationship in Namibia. 
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2.6 Patient management 
Patient management is one of the growing challenges of rapid ARV therapy scale up. In Sweden 
software for decision support called InfCare HIV was launched in 2004. Numerous functions are 
facilitated through structured data entry (Health Solutions, 2009). This software is now the largest 
common database and has also been launched internationally, in Denmark, Iceland, Russia and 
Finland. A structured patient booklet is used at Katutura Health Centre. This serves as the patient’s 
record where the clinical history is captured. The use of a structured or pro forma format may 
improve completeness by ≥ 50% and can be used  easily and with speed by clinicians (Schmidt, 
Rizvi, Lee, Wood, Amisano and Fairley, 2005; Diver & Craig, 2005 ; Natha, Sheey, Pollard, 
Parkianathan and Prime, 2008). Since the lack of complete, timely and accurate data impacts on 
site monitoring and national planning the structured format may assist in these aspects (Makombe 
et al, 2008). Tierney et al (2007) state that “one major obstacle in HIV/AIDS care in developing 
countries is the lack of electronic medical record systems to collect, manage and report clinical 
data”. They also aptly sited the various advantages of having such a system. Thus the Namibian 
MOHSS introduced AMIS an electronic medical record system at Katutura Health Centre in 
October 2008.  
 
There is limited literature on patient data management in Africa and the situation is not different in 
Namibia. However at the time of data collection the AMIS electronic version was just starting to be 
used and patient records had been loaded. Another problem of patient management is the loss to 
follow up rates that are high ranging from 5-25% in resource-poor settings that are scaling up ARV 
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therapy (Yu et al, 2007). No literature is available on the loss to follow up rates in ARV therapy in 
Namibia. 
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3. METHODOLOGY 
3.1 Study design 
An observational, cross-sectional and analytic study that utilised retrospective review of clinical 
records. Patient care booklets for adult patients initiated on HAART at the Katutura Health Centre 
from 1st of January to 31st
 
 of December 2007 were reviewed for a period of up to 12 months from 
the date the adult patient initiated HAART.  
3.2 Study population 
The study population was all adult patients enrolled in 2007 on first-line HAART as retrieved from 
the electronic medical record system, using the time frame as a search criterion. 
 
3.3 Sample size 
The Katutura Health Centre initiated ARV therapy on approximately 15 patients per week during 
2007, so total of 780 patient records was expected. To cover objectives 2- 4, the population 
comprised of records with a viral load result at 6 and/or 12 months. An assumption that at least 
50% of the records were complete was made based on findings from other studies (Schmidt et al, 
2005; Diver & Craig, 2005; Natha, Sheey, Pollard, Parkianathan and Prime, 2008). Unfortunately 
there are limited studies on data completeness and this is also true for Namibia. Then factoring in a 
maximum loss to follow up of 25%, then from 390 complete records only 293 were expected to 
also have a viral load result at 6 and/or 12 months. Madge et al (2008) have shown that 92% of 
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patients on HAART for more than 16 weeks have a viral load <50 copies/ml. San Lio et al (2008) 
revealed that 96.5% of patients on HAART had <1000 copies/ml at 12 months in Mozambique. 
Thus assuming a true value of 5% HAART failure within +/- 3% of the desired range a sample size 
of 212 would have been required as calculated on EpiInfo. Thus even factoring in maximum loss to 
follow up and completeness levels, the use of all expected records with a viral load at six and/or 12 
months was assumed to be adequate. 
 
3.4 Sampling procedure 
All 687 patient booklets for patients initiated on ARV therapy from 1st January 2007 to 31st
Exclusion: 
  
December 2007 were reviewed. Accordingly, a patient who was initiated on ARV therapy on 31 
December 2007 was followed to January 2009 to have a full 12 months record.  Below is the 
exclusion criteria applied. 
• All records with treatment switch/substitute within 12 month follow up period 
• All records were a patient is reported pregnant within the 12 month follow up period. 
• Prior ARV therapy 
 
A therapy substitute or switch involves a drug change which impacts virological outcome. In 
pregnancy a CD4 cut-off of 250cells/mm3 is used and this may result in a bias for outcome 
(MOHSS, 2007).  Using the above criteria a total of 508 records were eligible for inclusion. 
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To fulfill objectives 2-4 the following inclusion criteria was applied on the 508 records:  
• All records with viral load result at 6 months (5-7 month time frame) 
• All records with viral load result at 12 months (11-13 month time frame) 
The flexibility in the 6 and 12 month period was done to accommodate the laboratory turnaround 
time.  A total of 178 records at 6 months and 61 records at 12 months were eligible for inclusion. 
 
3.5 Data collection and processing 
The authorization letter provided from the MOHSS (Appendix 4) was presented to the manager at 
Katutura Health Centre. The purpose of the study was then explained to the staff members at the 
ARV clinic and a data collection schedule and data review location on site that suited the ARV 
clinic was adopted.  
 Key variables were defined and measured as follows: 
Self-reported adherence- 
 
Records of all patients initiated on ARV therapy from 1 January 2007 to 31 December 2007 were 
extracted from the AMIS electronic data management system using the time frame as a search 
criterion. The following variables were extracted:  
a) Demographics: sex, age, date of birth and treatment support. 
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b) Treatment profile: prior ART, date confirmed, date initiated on therapy, entry WHO 
stage, eligibility, start ART date, start weight, start WHO stage and start CD4.   
 
To fulfill objectives 2 to 4 each record was linked to a unique identifier. The data from the eligible 
record was extracted and entered into a customized Microsoft Excel spreadsheet linked to a unique 
identifier (Appendix 3). The following was data was extracted from each eligible record: 
a) Treatment monitoring characteristics: 
weight, WHO stage, tuberculosis, new opportunistic infection, adherence to prophylaxis, 
ARV adherence, viral load and CD4)  
Data verification was carried out periodically to ensure correctness and completion by reviewing 
previously entered files. A data clerk was hired to code viral load results into the < 40 copies/ml, 
40-399 copies/ml, 400- 999 copies/ml and > 1000 copies/ml categories for 10% of randomly 
selected eligible records from the study. The data clerk used the same data verification and data 
cleaning procedure as for the main study. The double coding task was done to assess the reliability 
of the study.  
 
3.6 Data cleaning and quality 
3.6.1 Data cleaning 
There is growing importance on Good Clinical Practice for issues of data handling and quality in 
clinical epidemiology research (Broeck, Cunningham and Herbst, 2005).  This study handled all its 
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data collection using a customized Microsoft Excel spreadsheet. The creation of a data collection 
tool before actual data collection was done to minimize data collection errors and assist in visual 
screening of data during collection and review. The process of data cleaning involves detecting, 
diagnosing and editing abnormalities (Broeck et al, 2005). Visual screening was done as a 
detection process through browsing of data tables searching for illogical results (biologically), 
outliers, date errors, classification errors, missing values and duplication. During the analysis phase 
frequency distributions and cross-tabulation were reviewed to identify data handling issues. 
 
Once a data handling issue was noted, a diagnosis process followed. Previous stages of data flow 
were revisited for any information that could justify the data point. The patient record was also 
reviewed at the earliest chance to verify the data point. Some outliers, for example in the viral load 
results were solved this way before data coding. Thus, all eligible records with a viral load were 
included and all missing values were represented. 
 
3.6.2 Data quality 
Data quality assessment can be subjective, reflecting the needs and experiences of people involved 
or objective, task-dependent or task-independent metrics (Pipino, Lee and Wang, 2002).  Objective 
data quality assessments involve the development of metrics utilizing simple ratio, minimum and 
maximum operation and weighted averages (Pipino et al, 2002). This study utilized a percentage of 
total outcomes over the desired outcomes to express the data quality dimension of completeness of 
data. A tabulation of this is included in the results section, Table 4.1. 
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3.7 Analysis 
A summary table for completeness of data, Table 4.1, was created using percentage calculations of 
obtained number of records over the expected number of records. The proportion of patient records 
in the cohort that had viral load results was then calculated as a percentage.  
 
First, the proportion of records with viral load at 6 months, 12 months, 6 and / or12 months and 
then finally the proportion of records with a result at both 6 and 12 months were calculated as a 
percentage. The distribution of viral load results at 6 and 12 months was then classified as 
proportions in the < 40 copies/ml, 40-399 copies/ml, 400- 999 copies/ml and >1000 copies/ml 
catergories. These categories were chosen due to the detection limit of the assay, viral load 
distribution variation in different settings and the “blip” phenomenon (WHO, 2000; Havlir et al, 
2001; Madge et al, 2008 and Phillips et al, 2008). The Wilcoxon rank test was applied to check for 
significance in the viral load distribution. 
 
The level of self-reported dose adherence at 6 and 12 months was classified as good (≥ %95), fair 
(85-94%) and poor (<85%) based on the patient care booklets (HIV Care/ART cards). The 
prevalence of ≥95% adherence at 6 and 12 months of initiating therapy was calculated as the 
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percentage of adherent patients (tally of all patients who self-reported ≥95% adherence at 6 or 12 
months) over the total number of patients in the sample population. The further classification based 
on the patient care booklets HIV Care/ ART cards (Appendix 1) of fair (85-94%) and poor (<85%) 
adherence was reported in a similar manner. The Wilcoxon rank test was again applied to check for 
significance in the adherence levels at the two time points. Adherence and viral load categories 
were then cross-tabulated and findings summarized. The prevalence ratio was calculated for each 
category instead of the prevalence odds ratio as an effect measure because it was reported to be 
conservative, consistent and interpretable by Thompson, Myers and Kriebe, 1998). Furthermore, 
the ideal statistic of incidence rate ratio can not be calculated in a cross sectional study (Thompson, 
Myers and Kriebe, 1998). The multivariate estimation utilized the Mantel-Haenszel test to 
determine estimated odds ratios and 95% CIs for patients who had treatment adherence ≤ 95% 
having a viral load ≥ 400 copies/ml, compared with patients who had treatment adherence of 
>95%. Patients with viral load ≥400 copies/ml were then compared with those with a viral load 
<400copies/ml at 6 and 12 months of initiating therapy using the Chi-square or Fisher’s exact test 
as appropriate. An alpha value of 0.05 was used in all statistical significance testing due to the 
recognition of small sample size in subpopulations analyzed (Peterson et al, 2007). All data was 
analyzed using SPSS version 8 statistical package.   
 
3.8 Validity 
The procedures have been well described to reflect a measurement that is as close to the true value 
as possible. Selection bias has been nearly negated with the use of all eligible records. The 
eligibility criteria have been minimal to ensure as great a number of records as possible are part of 
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the sampling frame. Unmeasured confounders may still affect the results since factors impacting 
adherence and viral load levels in this population have not been explored before to ensure inclusion 
of all relevant factors, however most potential confounders have been included in the data analysis. 
 
3.9 Reliability 
The reproducibility of measurement was done through use of the kappa coefficient for agreement 
of coding tasks.  Inter-observer bias and measures of inter-observer agreement are important 
sources of measurement error in this study (Landis & Koch, 1977). As the study data elements 
were captured through data coding the recommendation to use the kappa coefficient over the 
traditional retest measures of change in mean, typical error and retest correlation was adopted 
(Landis & Koch, 1977; Bloch & Kraemer, 1989; Hopkins, 2000; Di Eugenio, 2000). The 
consistency of classification of patient records into the data collection tool was performed on 10% 
of randomly selected eligible records due to time and cost constraints by a data clerk. Random 
numbers were generated from Microsoft Excel. A kappa coefficient of 1, P=0.000 was obtained, 
indicating excellent coding agreement. 
 
3.10 Generalisability 
The results of the study are only expected to apply to first-line ARV therapy patients enrolled for 
12 months at the Katutura Health Centre facility. The results however may have relevance in other 
similar settings. 
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3.11 Limitations 
The limitations of this study include the use of medical records. The level of completeness of 
medical records is a challenge. There is also no method applied to confirm the medical self-report 
being done by the patients which may have resulted in recall bias. Those that experienced therapy 
failure and had a treatment substitution or switch may have been non compliant to their treatment. 
Thus exclusion of the patients who substituted or switched therapy during the follow up may have 
introduced a selection bias. The exclusion was however done as the therapy substitute and switch 
data was not well coded in the records and there was an intensive operational research study under 
way at the time of this study, following up all the treatment failure patients. 
 
3.12 Ethical issues 
This study was based on record review.  Ethical approval was obtained from the MOHSS Research 
and Ethical Review Board (Appendix 4) and the University of Western Cape Ethics Committee 
(Appendix 5). Permission was also sought from the Sister-in Charge at the Katutura Health Centre 
to carry out the study. Confidentiality of patient records was maintained throughout the study. All 
research data was kept in a password locked database with limited access. All record review was 
carried out in a room next to the filing room with access restriction. The findings and 
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recommendations of the study are hoped to assist the management and care of patients on HIV 
ARV therapy not only at Katutura Health Centre but in Namibia. The study findings will be 
reported to the MOHSS and a feedback session will be scheduled for the Katutura Health Centre 
staff. 
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4. RESULTS 
A total of 687 patients were initiated on first-line HAART between January 1st and December 31st
4.1 Completeness of data 
, 
2007. All patients were followed-up for a period of up to12 months from the date of initiation of 
therapy through use of patient care booklet. Of the total population, 508 records were eligible. 
The completeness of the eligible records is shown below in Table 4.1. 
Table 4.1: Completeness of baseline data collected  
 
Table 4.1: Completeness of Baseline data collected 
Variable 
Study population 
N = 508 
n (%)* 
6 month viral load 
population, N = 178  
         n (% )* 
12 month viral load 
population, N = 61 
n (%)* 
Sex 508 (100) 178 (100) 61 (100) 
Age 508 (100) 178 (100)  61 (100)  
Treatment supporter 508 (100) 178 (100) 61 (100) 
Entry WHO stage 488 (96.1) 171 (96.1) 60 (98.3) 
Eligibility criteria 467 (91.9) 167 (93.8) 55 (90.1) 
Start Weight 453 (89.2) 161 (90.4)   54 (88.5)  
Start CD4 460 (90.6)   165 (92.7) 56 (91.8) 
(%)
The percentage completeness baseline data of eligible records in the overall population and the 
population with viral load result at 6 and 12 months are comparable. The variables sex, age and 
treatment supporter had completeness levels of 100% across the study population and sub 
populations. The  variables entry WHO stage, eligibility criteria, start weight and start CD4 had 
levels of completeness that were within +/- 2% of the main study population. The lowest level of 
* The percentage completeness of the data in the specific population (for example: completeness of 
sex variable in the population with a 6 month viral load result (178/178= 100% completeness). 
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completeness was with the start weight variable in the sub population of 12 month viral load. The 
data on height measurements were missing in the records. Thus body mass index was not 
calculated. 
 
4.2 Baseline characteristics of study participants 
The baseline characteristics of 508 eligible patient records are summarized below. The baseline 
characteristics of the eligible patients at initiation of therapy showed that 53% were male. Their age 
had a median of 36 (IQR: 33-43) years. Most patients had a treatment supporter (72%), were at 
WHO stage 1 at initiation of treatment (37%) and were eligible for therapy based on CD4 count 
and clinical picture (68%). Their start CD4 count had a median of 460 (IQR: 80.3-192) cell/mm3
  
 
while their start weight had a median of 57 (IQR: 50.5-62.1) kg.  
 
 
 
 
  
37 
 
 
Table 4.2: Baseline characteristics of study participants 
Characteristic Frequency 
Sex n=508:   
Male 267 (53) 
Female 241 (47) 
    
Age (years) n=508:   
Median 36 
IQR 33-43 
    
Treatment supporter n=508:   
Yes 364 (72) 
No 144 (28) 
    
Entry WHO stage n=488   
1 189 (37) 
2 101 (20) 
3 118 (23) 
4 80 (16) 
Missing 20 (4) 
 
   
Eligibility criteria n=467   
CD4 only 5 (1) 
Clinical only 115 (23) 
CD4 and Clinical 347 (68) 
Missing 41 (8) 
    
Start CD4 count cell/mm3   n=460 
Median 153.8  
IQR  80.3-192 
    
Start weight (kg) n=453   
Median 57 
IQR 50.5-62.1 
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4.3 The distribution of viral load results at the two time points (6 and 12 months) after initiation 
of therapy  
 
Table 4.3: Distribution of viral load at 6 and 12 months according to 
viral load categories 
Viral load (copies/ml) 6 months 
n=178 
12 months 
n=61 
<40, n (%) 101 (57%) 19 (31%) 
40 – 399, n (%) 55 (31%) 24 (39%) 
400-1000, n (%) 7 (4%) 11 (18%) 
>1000, n (%) 15 (8%) 7 (12%) 
 
Table 4.3 summarizes the distribution of viral load results at 6 months (n= 178) and 12 months 
(n=61). At 6 months, 101 (57%) patients had viral load counts less than 40 copies/ml, 55 (31%) 
had a count of 40-399 copies/ml. Counts of 400-999 copies/ml were observed in 7 (4%) patients 
and 15 (8%) had counts that exceeded  >1000 copies/ml at 6 months. At 12 months, 19 (31%) 
patients had viral load counts less than 40 copies/ml, 24 (39%) had a count of 40-399 copies/ml. 
Counts of 400-999 copies/ml were observed in 11 (18%) patients and 7 (12%) had counts that 
exceeded  >1000 copies/ml at 12 months. 
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Wilcoxon signed ranked test was applied and a P value of 0.092 for 12 months viral load being less 
than 6 months viral load was obtained. 
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4.4 The self-reported dose adherence levels to first- line ARV therapy at two time points (6 and 
12 months) after initiation of therapy 
Table 4.4 shows the distribution of self- reported ARV adherence at 6 and 12 months time points.  
Table 4.4: Distribution of patient self reported ARV dose adherence at 6 and 
12 months 
Category 6 months 
n=176 
12 months 
n=140 
 
Good (≥95 %), n (%) 148 (84) 123 (88) 
Fair (85- 94 %), n (%)  13 (7) 4 (3) 
Poor (≤84 %), n (%) 15 (9) 13 (9) 
 
Table 4.4 shows that at 6 months 84% of 176 patients self-reported a good (≥ 95%) ARV dose 
adherence, while 7% self-reported fair (85- 94 %) and 9% self-reported poor (≤84 %), ARV dose 
adherence.  At 12 months 88% of 140 patients self-reported a good ARV dose adherence, while 3% 
self-reported fair (85- 94 %) and 9% self-reported poor (≤84 %), ARV dose adherence.  Wilcoxon 
signed ranked test was applied and a P value of 0.179 was obtained. 
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4.5 The characteristics and comparison of patients with viral load < 400 copies/ml and ≥ 400 
copies/ml at the 6 and 12 months after initiation of therapy. 
Table 4.5 shows the characteristics and comparison of patients with viral load < 400 copies/ml and 
≥400 copies/ml at 6 and 12 months.  
 
Table 4.5: Tabulation of characteristics and a comparison of patients with viral load < 400 
copies/ml and ≥ 400 copies/ml at the 6 and 12 months. 
Characteristic Viral load at 6 months  Viral load at 12 months  
 < 400 
copies/ml 
≥ 400 
copies/ml 
p value < 400 
copies/ml 
≥ 400 
copies/ml 
p value 
Gender:   0.323   0.243 
Male 87 14  18 10  
Female 69 8  25 8  
       
Treatment supporter   0.551   0.279 
Yes 115 16  31 15  
No 41 6  12 3  
       
WHO Stage   0.439   0.580 
1 63 6  20 10  
2 35 4  11 2  
3 35 8  6 4  
4 17 3  5 2  
       
Eligibility   0.200   0.339 
CD4 only 1 1     
Clinical and CD4 113 16  30 13  
Clinical only 33 3  7 5  
       
TB   0.089    
Yes 3 2  2 0 0.430 
No 130 14  29 16  
       
*Fisher’s exact test 
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Table 4.5: Tabulation of characteristics and a comparison of patients with viral load < 400 
copies/ml and ≥ 400 copies/ml at the 6 and 12 months continued…. 
Characteristic Viral load at 6 months  Viral load at 12 months  
 < 400 
copies/ml 
≥ 400 
copies/ml 
p value < 400 
copies/ml 
≥ 400 
copies/ml 
p value 
New OI       
Yes 7 0 0.444 0 1 0.340 
No 126 16  31 15  
       
self-reported 
cotrimoxazole adherence 
  0.000    
Good ≥ 95% 112 11  28 7 0.001 
Fair 85-94% 6 2  1 3  
Poor <85 3 5  0 4  
       
self-reported ARV 
adherence 
      
Good ≥ 95% 117 8 0.000 31 8 0.000 
Fair 85-94% 9 2  0 3  
Poor <85 5 8  1 5  
       
*Fisher’s exact test 
Table 4.5 summarises the characteristics and comparison of patients with viral load <400 copies/ml 
and ≥ 400 copies/ml in the 6 months and 12 months categories. Poor virological outcome at 6 
months was not significantly different according to gender (P=0.323), treatment supporter (P= 
0.551), WHO stage (P=0.439), eligibility criteria (P=0.2), presence of TB (P=0.089) and presence 
of a new opportunistic infection (P=0.444). At 12 months, no statistically significant association 
was found with gender (P=0.243), treatment supporter (P= 0.279), WHO stage (P=0.58), eligibility 
criteria (P=0.339), presence of active TB (P=0.430) and presence of a new opportunistic infection 
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(P=0.340). Poor virological outcome at both 6 and 12 months was associated with self-reported 
cotrimoxazole adherence and self-reported ARV dose adherence, p<0.005 using the 95% 
confidence level. 
 
 
Table 4.6: Cross tabulation of virological response using 400 copies/ml threshold and self-
reported ARV dose adherence at 6 months 
  Viral load copies/ml  
<400 ≥400 Total 
Self-reported 
ARV Adherence 
≥ 95% 117 8 125 
< 95% 14 10 24 
 Total 131 18 149 
 
The prevalence ratio = 1.60, probability of having a viral load less than 400 copies/ml is 1.60 times 
higher for those patients with ≥ 95% ARV adherence than those with < 95% ARV adherence. 
When Mantel-Haenszel test was applied at the six month time point, the odds of a viral load of 
>400 copies/ml and a self-reported dose adherence of <95% had a value of 2.346 (CI:1.264-3.429), 
P=0.000.  
 
 
 
 
  
44 
  
 
Table 4.7: Cross tabulation of virological response using the 1000 copies/ml threshold and 
self-reported ARV dose adherence at 6 months 
  Viral load copies/ml  
<1000 ≥1000 Total 
Self-reported 
ARV Adherence 
≥ 95% 120 5 125 
< 95% 17 7 24 
  Total 156 12 149 
 
The prevalence ratio = 1.36, the probability of having a viral load less than 1000 copies/ml is 1.36 
times higher for those patients with 95% and above ARV adherence than those with less than 95% 
ARV adherence. When Mantel-Haenszel test was applied at the six month time point, the odds of a 
viral load of >1000 copies/ml and a self-reported dose adherence of <95% had a value of 2.291 
(CI: 1.036-3.546), P=0.000.  
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Table 4.7: Cross tabulation of virological response using 400 copies/ml threshold and self-
reported ARV dose adherence at 12 months 
  Viral load copies/ml  
<400 ≥400 Total 
Self-reported 
ARV Adherence 
≥ 95% 31 8 39 
< 95% 1 8 9 
 Total 32 16 48 
 
The prevalence ratio =7.15, the probability of having a viral load less <400 copies/ml is 7.15 times 
higher for those patients with ≥ 95% and above ARV adherence than those with < 95% ARV 
adherence. When Mantel-Haenszel test was applied at the 12 month time point, the odds of a viral 
load of >400 copies/ml and a self-reported dose adherence of <95% had a value of 3.434 (CI: 
1.215-5.653), P=0.000. 
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Table 4.7: Cross tabulation of virological response using the 1000 copies/ml threshold and 
self-reported ARV dose adherence at 12 months 
  Viral load copies/ml  
<1000 ≥1000 Total 
Self-reported 
ARV Adherence 
≥ 95% 36 3 39 
< 95% 5 4 9 
 Total 41 7 48 
 
The prevalence ratio =1.66, the probability of having a viral load <1000 copies/ml is 1.66 times 
higher for those patients with ≥95% ARV adherence than those with < 95% ARV adherence. 
When Mantel-Haenszel test was applied at the 12 month time point, the odds of a viral load of 
>1000 copies/ml and a self-reported dose adherence of <95% had a value of 2.262 (CI: 0.497-
4.027), P=0.023.  
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 5. DISCUSSION 
This study sought to determine viral load distribution and self-reported dose adherence to first-line 
HAART at two time points (6 and 12 months after initiation of HAART therapy). Futhermore, the 
study sought to characterize and compare adult patient virological outcome at 6 months and 12 
months time points. The exclusion criteria was based on treatment substitute or switch and reported 
pregnancy. The completeness of data is the first topic of discussion in the following section. 
 
5.1 Completeness of data 
The completeness of baseline data variables for categorized eligible records ranged from 88.5% 
(CD4 count at the 12 months in records with a viral load result) to 100% for sex, age and treatment 
supporter variables. The completeness levels showed that the categorization of records into those 
with 6 months and 12 months viral load result did not introduce a selection bias based on level of 
completeness. The high level of completeness (>80 %) may also indicate rigor being placed in data 
completeness at initiation of ARV therapy. The rigor in completeness of data seems to have been 
lost in the treatment monitoring stage as indicated by the recommended follow up of a 6 month 
viral load only having 178 eligible records. This may be attributed to workload pressure on the 
healthcare worker despite use of the structured patient care booklet. Unfortunately, the level of 
completeness of data may impact negatively on site monitoring and national planning (Makombe et 
al, 2008).  
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5.2 Baseline characteristics of study participants 
The baseline characteristics of the eligible patients at initiation of therapy showed that the uptake 
of the ARV therapy at Katutura Health Centre is balanced between the sexes (53% male). Most 
patients, 72% had a treatment supporter. However a clear population of 28% was initiated on ARV 
therapy despite lack of one. The initiation of patients without a treatment supporter is a reflection 
of the implementation of the ARV guidelines which recommend that lack of a treatment supporter 
should not be the sole reason for denying therapy (MOHSSa, 2008).  
 
The WHO staging shows initiation of ARV therapy being most frequent at stage 1 (37%), but with 
stage 2 (20%) and stage 3 (23%) initiation being comparable. The WHO stage 4 has the lowest rate 
(16%) of initiation of ARV therapy. The reported WHO stages of initiation of therapy showed that 
most patients are initiated before they reach stage 4 is ideal for delay of HIV progression. While 
4% did not have a WHO stage recorded, this may be an effect of medical record data completeness. 
When the eligibility criteria for initiation is analysed it is clear that most patients (68%) were 
HAART-initiated based on CD4 count and clinical picture (WHO staging). This may account for 
the comparable initiation of ARV therapy at WHO stages 2 and 3. The baseline CD4 count had a 
median of 154 (IQR: 80 to 192) cells/mm3 which correlates well with the MOH guidelines of using 
200 cells/mm3
 
 as a cutoff.  Even though a median weight of 57 kg is reported, BMI would have 
been a better indicator as it takes into account gender variability of weight.  
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5.3 The distribution of viral load results at the two time points (6 and 12 months) after initiation 
of therapy  
Of the 508 eligible records 35% had a viral load result at 6 months and only 12% had viral load 
results at 12 months. The majority of recorded viral load results were at 6 months which is in 
keeping with MOHSS guidelines to test for viral load at 6 months (MOHSSa, 2008; MOHSS, 
2005). However, despite the MOH recommendations, the uptake of virological monitoring was 
only 35%. The low uptake of the viral load tool may indicate a need for training clinicians in the 
use of virological monitoring.  
 
The distribution of viral load at 6 and 12 months after initiating HAART was summarized in 
categories. These categories were chosen due to the detection limit of the assay, viral load 
distribution variation in different settings and the “blip” phenomenon (Madge et al, 2008; Phillips 
et al, 2008; WHO, 2000;. San Lio et al, 2008). The viral load distribution showed 57% of records 
had undetectable copies/ml at 6 months versus 31% of records at 12 months.  Then 88% of records 
had < 400 copies/ml at 6 months and 70% of records at 12 months. When the 1000 copies/ml cut 
off was applied, 92% of records had <1000 copies/ml at 6 months and 88% of records at 12 
months. The viral load distribution findings in this study are different from an earlier report by  
Madge et al (2008) where 92% of patients on therapy for more than 16 weeks had a viral load of 
<50 copies/ml (Madge et al, 2008). It must be noted however that the study of Madge et al (2008) 
was carried out in a resource unlimited setting. The resource setting may account for the greater 
number of patients with suppressed viral load.  
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The viral load distribution findings indicate that the more conservative thresholds for viral load 
suppression of 400 copies/ml or 1000 copies/ml may need to be used in Namibia instead of the 
assay detection limit of 40 copies/ml. Madge et al (2008) and Phillips et al (2008) have already 
proposed the use of a conservative viral load threshold of 400 copies/ml to accommodate the “blip” 
phenomenon. Moreover other studies have already shown that the “blip” phenomenon does not 
warrant therapy change (Havlir et al, 2001; Lee, Keiffer, Siliciano and Nettles, 2006). In a study 
carried out in Mozambique the outcome of virological failure was placed at a viral load threshold 
of 1000 copies/ml (San Lio et al, 2008) versus the more stringent level of the detection limit of the 
assay. Thus, based on the current study findings and previous study findings there is evidence for 
the feasibility of using the more conservative thresholds.  
 
There was at tendency for lower viral load results at 12 months compared to 6 months but the 
results did not reach statistical difference, P=0.092. Lower viral load results are expected in 
patients that are on successful ARV therapy as the goal of ARV therapy is undetectable viral load 
(WHO, 2000). A prospective study to follow the virological outcomes of patients on ARV therapy 
is required to determine possible confounders to obtaining undetectable viral load after initiation of 
therapy. 
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5.5 The self-reported ARV dose adherence levels to first line ARV therapy at two time points (6 
and 12 months) 
A high level of self-reported ARV dose adherence was observed at the two time points: 84% at 6 
months and 88% at 12 months for ≥ 95% of medications taken in the past three days. The self-
reported dose adherence findings dispel concerns of Stevens, Kay and Corrah, (2004), since rapid 
access to ARV therapy in Namibia did not led to poorly adhered to treatment regimens not clear 
what you mean. The high adherence levels of patients initiated on ARV therapy in 2007 is 
encouraging increased ARV therapy rollout using the current guidelines. The presence of good 
adherence levels are in agreement with findings from Mills et al, (2006) meta-analysis of 
adherences studies in Africa. Their study showed adherence levels of 77.1%. However, the higher 
adherence findings of the current study may be due to the overestimation of the self-reported dose 
adherence measure (Liu et al, 2006). Unfortunately the exact margin of overestimation is not 
known and thus highlights why adherence measurements are less objective than virological 
monitoring (Garcia et al, 2006). 
 
The sustainability of good ARV dose adherence is a challenge with many determinants ((Pinheiro, 
de-Carvalho-Leite, Drachler and Silveira, 2002; Amberbir et al, 2008; Gordillo, del Amo, Soriano 
and Gonzalez-Lahoz, 1999; Duong et al, 2001; Bonolo et al, 2005; Nilsson et al, 2006; Weiser et 
al, 2003; Laniece et al, 2003). The determinants of adherence in the current study were only 
incorporated as far the scope allowed. Hence a comprehensive study of determinants of ARV 
therapy adherence in Namibia would be invaluable.  
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5.6 The description of patients with viral load ≥400 copies/ml at the 6 and 12 months. 
The study showed that poor virological outcome of a viral load ≥400 copies/ml was significantly 
associated at 6 months and 12 months with self-reported prophylaxis adherence and self-reported 
ARV dose adherence.  Thus self-reported prophylaxis adherence and self-reported ARV dose 
adherence are predictors of poor virological outcome at both 6 and 12 months time points. The lack 
of change in determinants of adherence at the two time points is in disagreement with the findings 
by Amberbir et al (2008). The study findings agree with those of Chi et al (2009) and San Lio et al 
(2008) who reported that individuals >35 years of age or reported social support (an adherence 
buddy) were less likely to exhibit poor clinical outcome. However, it must be highlighted that the 
definition of poor virological outcome for San Lio et al (2009) was a viral load >1000 copies/ml. 
 
Fielding et al (2008) reported poor virological outcome of a viral load ≥400 copies/ml at 12 months 
to be associated with  older age, lower weight, <1 log decrease in viral load at six weeks, WHO 
stage 3 and 4, baseline viral load at baseline > 100000 copies/ml and site of ARV therapy delivery. 
The current study found no association with age. Unfortunately the other factors found to be 
associated with poor virological outcome by Fielding et al (2008), log decrease at 6 weeks and 
baseline viral load were not determined in this study as they are not accessed in the Namibian 
setting.  
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Cross-tabulation of virological response and self-reported dose adherence at 6 and 12 months was 
done.  The prevalence ratio shows the probability of a viral load of <400 copies/ml with ≥ 95% 
self-reported adherence increasing from 1.66 times at 6 months to 7.15 times at 12 months. 
However the prevalence ratio does not show a dramatic increase when a threshold of <1000 
copies/ml is used, with values of 1.36 times at 6 months and 1.66 at 12 months. The odds of a viral 
load >400 copies/ml or >1000 copies/ml, when self –reported ARV adherence is < 95% , shows 
significant association at 6 months and 12 months, P<0.05. Thus the study findings are consistent 
with those of San Lio et al (2008).  
 
5.7 Study limitations 
The measurement of adherence is difficult. Even though self-reporting of >95% of medication in 
the past three days is widely used it has been shown to overestimate adherence levels (Liu et al, 
2006). The assessment of causal relationships was limited due to use of a retrospective approach 
that is associated with limitations such as selection bias, missing or incomplete information 
(Peterson et al, 2007). Though the completeness of the data was not guaranteed, based on the 
limited studies done an increased level of completeness was expected due to the use of a structured 
format for patient consultations. The quality of the data was expected to be of good quality since 
two senior clinicians are stationed at this site. The study findings are limited to the study setting. 
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6. CONCLUSION 
The distribution of viral load results showed that 35% of the 508 eligible records initiated on ARV 
therapy in 2007 had a viral load result taken at 6 month time versus 12% of the 508 eligible records 
at 12 months. This reflects a low uptake of the virological monitoring tool recommended for an 
ARV therapy patient management at 6 months. Based on viral load distribution patterns a 
conservative viral load threshold of 400 copies/ml (or 1000 copies/ml) may need to be used for 
virological response assessment in the Namibian setting. The current adherence level of >80% self-
reported dose adherence for patients initiated on ARV therapy encourages increased ARV therapy 
rollout using the current guidelines. Poor virological outcome of viral load ≥400 copies/ml was 
associated with lower self-reported prophylaxis adherence and self-reported ARV dose adherence 
at 6 and 12 months. Thus self-reported adherence is a predictor of poor virological outcome at both 
6 and 12 months time points.  
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7. RECOMMENDATIONS 
The following recommendations are drawn from this study: 
 Due to poor uptake of virological monitoring as a tool, training of clinicians in the use of this tool 
is recommended. 
 A conservative viral load threshold of 400 copies/ml or 1000 copies/ml should be used for 
virological response assessment in the Namibian setting. 
 Self-reported ARV dose adherence may be used as a predictor of poor virological outcome at 6 
and 12 months. 
 A prospective study to determine predictors of poor virological outcome and adherence and 
possible confounders is encouraged. 
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Appendix 2:  Frequency and use of HIV viral load 
CLINICAL INDICATION INFORMATION USE 
Syndrome consistent with 
acute HIV infection 
Establishes diagnosis when 
HIV antibody is negative or 
indeterminate 
diagnosis 
Initial evaluation of newly 
diagnosed HIV infection 
Baseline viral load set point Use as baseline information 
Every 3-4 months in patients 
not on therapy 
Changes of viral load Use as continued  monitoring 
or baseline value if therapy is 
to be initiated 
2-8 weeks of initiation or 
change of therapy 
Initial assessment of drug 
efficacy 
Decision to continue or 
change therapy 
3-4 months after start of 
therapy 
Assessment of virologic effect 
of therapy 
Decision to continue or 
change therapy 
Every 3-4 months for patients 
on therapy 
Durability of antiretroviral 
effect 
Decision to continue or 
change therapy 
Clinical event or significant 
decline in CD4 T-cells 
Association with changing or 
stable viral load 
Decision to initiate, continue 
or change therapy 
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Appendix 3: Data collection tool 
Demographics 
UNIQUE 
NUMBER SEX AGE DATE OF BIRTH Tx SUPPORTER 
 
Treatment Profile 
UNIQUE 
NUMBER 
PRIOR 
ART 
DATE 
CONFIRMED 
DATE 
ENROLLED 
ENRTY WHO 
STAGE  ELIGIBLITY 
START ART 
DATE 
START 
WEIGHT 
 
START WHO 
STAGE 
START 
CD4 
SUB IN IST 
LINE 
SUB IN IST LINE 
CODE 
SUB IN 1ST LINE 
DATE 
SWITCH 
LINE 
SWITCH 
DATE 
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Characteristics 
 
UNIQUE NUMBER 
Weight WHO Stage TB  New OI 
6months 12months 6months 12months 6months 12months 6months 12months 
 
ARV adherence Viral load CD4 Adherence Cotri Tx Pregnancy 
6months 12months 6months 6months 12months 6months 6months 12months 6months 12months 
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Appendix 4: Namibian Ministry of Health and Social Services Ethical Clearance  
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Appendix 5: University of the Western Cape Higher Degrees Committee Ethical Clearance  
 
 
 
 
